The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Works by Vorobeychik, G
Results: 2
1
2
P.011 Efficacy and safety of ravulizumab in adults with AQP4+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial.
- Published in:
- 2024
- By:
- Publication type:
- Abstract